Stock comparison
Medtronic
TG Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MDT
Medtronic
Market cap
$97.77B
Sector
Healthcare
TGTX
TG Therapeutics
Market cap
$6.51B
Sector
Healthcare
Overall winner
TG Therapeutics TGTX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MDT | TGTX | Winner |
|---|---|---|---|
| Warren Buffett | 58D | 49D | MDT |
| Benjamin Graham | 63C | 62D | MDT |
| Philip Fisher |
Side-by-side metrics
| Metric | MDT | TGTX |
|---|---|---|
| Market cap | $97.77B | $6.51B |
| P/E (TTM) | 21.2x | 13.3x |
| EV/EBIT | 20.9x | 55.3x |
| ROIC (TTM) | 6.43% | 11.13% |
| Gross margin | 61.95% | 83.04% |
| Net margin | 13.0% | 65.95% |
| Revenue CAGR 5y | 2.73% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MDT leads on
- Dividend yield3.73%vs 0.0%+100%
- Market cap$97.77Bvs $6.51B+93%
- EV/EBIT20.9xvs 55.3x+62%
- Debt / Equity0.6xvs 1.3x
More like TGTX
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.